Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$8.61
-0.12-1.37%
At close: -
$8.55
-0.06-0.70%
After Hours: 5:27 PM EDT
Comments
Loading...
Nektar Therapeutics Analyst Ratings and Price Targets | NASDAQ:NKTR | Benzinga
Nektar Therapeutics has a consensus price target of $4.5 based on the ratings of 11 analysts. The high is $7 issued by Piper Sandler on November 4, 2024. The low is $2 issued by Jefferies on April 11, 2025. The 3 most-recent analyst ratings were released by Jefferies, Oppenheimer, and HC Wainwright & Co. on April 11, 2025, March 14, 2025, and March 13, 2025, respectively. With an average price target of $4.83 between Jefferies, Oppenheimer, and HC Wainwright & Co., there's an implied -43.47% downside for Nektar Therapeutics from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
Oppenheimer
HC Wainwright & Co.
B. Riley Securities
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Nektar Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/11/2025 | Buy Now | -76.61% | Jefferies | Roger Song36% | $1 → $2 | Upgrade | Hold → Buy | Get Alert |
| 03/14/2025 | Buy Now | -29.82% | Oppenheimer | Jay Olson60% | → $6 | Upgrade | Perform → Outperform | Get Alert |
| 03/13/2025 | Buy Now | -23.98% | HC Wainwright & Co. | Arthur He35% | $6.5 → $6.5 | Reiterates | Buy → Buy | Get Alert |
| 02/25/2025 | Buy Now | -23.98% | HC Wainwright & Co. | Arthur He35% | $6.5 → $6.5 | Reiterates | Buy → Buy | Get Alert |
| 01/13/2025 | Buy Now | -23.98% | HC Wainwright & Co. | Arthur He35% | $6.5 → $6.5 | Reiterates | Buy → Buy | Get Alert |
| 01/08/2025 | Buy Now | -53.22% | B. Riley Securities | Mayank Mamtani72% | → $4 | Initiates | → Buy | Get Alert |
| 11/04/2024 | Buy Now | -18.13% | Piper Sandler | Yasmeen Rahimi60% | → $7 | Initiates | → Overweight | Get Alert |
| 09/30/2024 | Buy Now | -53.22% | BTIG | Robert Hazlett33% | → $4 | Assumes | → Buy | Get Alert |
| 03/06/2024 | Buy Now | -88.3% | Jefferies | Roger Song36% | $0.5 → $1 | Maintains | Hold | Get Alert |
| 11/20/2023 | Buy Now | — | JP Morgan | Jessica Fye67% | — | Reinstates | → Underweight | Get Alert |
| 11/09/2023 | Buy Now | — | TD Cowen | Chris Shibutani55% | — | Upgrade | Market Perform → Outperform | Get Alert |
| 08/07/2023 | Buy Now | -29.82% | Mizuho | Mara Goldstein56% | → $6 | Reiterates | → Neutral | Get Alert |
| 05/10/2023 | Buy Now | -88.3% | Jefferies | Roger Song36% | $1.5 → $1 | Upgrade | Underperform → Hold | Get Alert |
| 03/06/2023 | Buy Now | -64.91% | Oppenheimer | Jay Olson60% | $5 → $3 | Maintains | Perform | Get Alert |
| 02/27/2023 | Buy Now | -76.61% | Goldman Sachs | Chris Shibutani55% | $3 → $2 | Maintains | Sell | Get Alert |
| 02/24/2023 | Buy Now | -64.91% | SVB Leerink | Daina Graybosch43% | $5 → $3 | Maintains | Market Perform | Get Alert |
| 02/24/2023 | Buy Now | -82.46% | Jefferies | Roger Song36% | $3.2 → $1.5 | Downgrade | Hold → Underperform | Get Alert |
| 08/08/2022 | Buy Now | — | JP Morgan | Jessica Fye67% | — | Downgrade | Neutral → Underweight | Get Alert |
FAQ
What is the target price for Nektar Therapeutics (NKTR) stock?
The latest price target for Nektar Therapeutics (NASDAQ:NKTR) was reported by Jefferies on April 11, 2025. The analyst firm set a price target for $2.00 expecting NKTR to fall to within 12 months (a possible -76.61% downside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Nektar Therapeutics (NKTR)?
The latest analyst rating for Nektar Therapeutics (NASDAQ:NKTR) was provided by Jefferies, and Nektar Therapeutics upgraded their buy rating.
When was the last upgrade for Nektar Therapeutics (NKTR)?
The last upgrade for Nektar Therapeutics happened on April 11, 2025 when Jefferies raised their price target to $2. Jefferies previously had a hold for Nektar Therapeutics.
When was the last downgrade for Nektar Therapeutics (NKTR)?
The last downgrade for Nektar Therapeutics happened on February 24, 2023 when Jefferies changed their price target from $3.2 to $1.5 for Nektar Therapeutics.
When is the next analyst rating going to be posted or updated for Nektar Therapeutics (NKTR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nektar Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nektar Therapeutics was filed on April 11, 2025 so you should expect the next rating to be made available sometime around April 11, 2026.
Is the Analyst Rating Nektar Therapeutics (NKTR) correct?
While ratings are subjective and will change, the latest Nektar Therapeutics (NKTR) rating was a upgraded with a price target of $1.00 to $2.00. The current price Nektar Therapeutics (NKTR) is trading at is $8.55, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
